

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2804299

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MICHAEL G. BRAMUCCI	02/04/2014
LORI ANN MAGGIO-HALL	02/19/2014
ANDREW C. ELIOT	02/21/2014
CHARLES E. NAKAMURA	02/27/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BUTAMAX ADVANCED BIOFUELS LLC
<b>Street Address:</b>	ROUTE 141 & HENRY CLAY
<b>Internal Address:</b>	DUPONT EXPERIMENTAL STATION BLDG. 356
<b>City:</b>	WILMINGTON
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19880-0356
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14179826
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(302)351-7299
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	302-999-6883
<b>Email:</b>	INEZ.T.CHARLES@DUPONT.COM
<b>Correspondent Name:</b>	CHRISTINE M. LHULIER
<b>Address Line 1:</b>	974 CENTRE ROAD
<b>Address Line 2:</b>	CHESTNUT RUN PLAZA 721/2333
<b>Address Line 4:</b>	WILMINGTON, DELAWARE 19805
<b>ATTORNEY DOCKET NUMBER:</b>	CL3926USCNT2
<b>NAME OF SUBMITTER:</b>	INEZ T. CHARLES
<b>SIGNATURE:</b>	/INEZ T. CHARLES/
<b>DATE SIGNED:</b>	04/08/2014
<b>Total Attachments: 4</b>	
source=20140402_CL3926USCNT2_ExecutedAssignment#page1.tif	

PATENT

source=20140402\_CL3926USCNT2\_ExecutedAssignment#page2.tif

source=20140402\_CL3926USCNT2\_ExecutedAssignment#page3.tif

source=20140402\_CL3926USCNT2\_ExecutedAssignment#page4.tif

**PATENT**

**REEL: 032623 FRAME: 0894**

## ASSIGNMENT

We/I, the undersigned,

Michael G. Bramucci, Andrew C. Eliot, Lori Ann Maggio-Hall, Charles E. Nakamura

(hereafter referred to as the Assignor(s))

for valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell, assign, and transfer to Butamax Advanced Biofuels LLC, a corporation organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Wilmington, Delaware (hereafter referred to as the Assignee), his/her entire right, title, and interest in and to

United States Patent Application No. 14179826, filed on February 13, 2014  
and which is identified as Case Number CL3926USCNT2, entitled  
"A Butanol Dehydrogenase Enzyme from the Bacterium Achromobacter xylosoxidans"

in any and all patent applications thereon including non-provisional applications, continuations, continuations-in-part, divisionals, in any and all Letters Patent(s) therefor, reissues, extensions, renewals, and reexaminations of the patent application or Letters Patent therefor, in any and all inventions, whether joint or sole, disclosed therein, any priority rights derived from the aforesaid patent application for Letters Patent by virtue of the International Convention for the Protection of Industrial Property and any other treaty or understanding for intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, any and all applications for Letters Patent for any such inventions in any country whatsoever, any and all patents for any such inventions in any country whatsoever; and the sole right to file such patent applications in its name or ours, file such applications under the aforesaid International Convention or other treaty or understanding, have said patents granted in its name or ours, and enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future. All such rights, title, and interest to be held and enjoyed by the Assignee, its successors, assigns, legal representatives to the same extent as all such rights, title, and interest would have been held and enjoyed by the Assignor(s) had this assignment and sale not been made

We/I, the undersigned, agree, whenever requested, to communicate to Assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers, or instruments necessary or required by Assignee, its successors, assigns, and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid Assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

Michael G. Bramucci (L.S.)  
Michael G. Bramucci

DATE: 4/2/2014

\_\_\_\_\_(L.S.)  
Andrew C. Eliot

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Lori Ann Maggio-Hall

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Charles E. Nakamura

DATE: \_\_\_\_\_

## ASSIGNMENT

We/I, the undersigned,

Michael G. Bramucci, Andrew C. Eliot, Lori Ann Maggio-Hall, Charles E. Nakamura


(hereafter referred to as the Assignor(s))

for valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell, assign, and transfer to Butamax Advanced Biofuels LLC, a corporation organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Wilmington, Delaware (hereafter referred to as the Assignee), his/her entire right, title, and interest in and to

United States Patent Application No.14179826, filed on February 13, 2014  
and which is identified as Case Number CL3926USCNT2, entitled  
"A Butanol Dehydrogenase Enzyme from the Bacterium Achromobacter xylosoxidans"

in any and all patent applications thereon including non-provisional applications, continuations, continuations-in-part, divisionals, in any and all Letters Patent(s) therefor, reissues, extensions, renewals, and reexaminations of the patent application or Letters Patent therefor, in any and all inventions, whether joint or sole, disclosed therein, any priority rights derived from the aforesaid patent application for Letters Patent by virtue of the International Convention for the Protection of Industrial Property and any other treaty or understanding for intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, any and all applications for Letters Patent for any such inventions in any country whatsoever, any and all patents for any such inventions in any country whatsoever; and the sole right to file such patent applications in its name or ours, file such applications under the aforesaid International Convention or other treaty or understanding, have said patents granted in its name or ours, and enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future. All such rights, title, and interest to be held and enjoyed by the Assignee, its successors, assigns, legal representatives to the same extent as all such rights, title, and interest would have been held and enjoyed by the Assignor(s) had this assignment and sale not been made

We/I, the undersigned, agree, whenever requested, to communicate to Assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers, or instruments necessary or required by Assignee, its successors, assigns, and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid Assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

_____(L.S.)	 _____(L.S.)
Michael G. Bramucci	Andrew C. Eliot
DATE: _____	DATE: <u>21 Feb 2014</u>
_____(L.S.)	_____(L.S.)
Lori Ann Maggio-Hall	Charles E. Nakamura
DATE: _____	DATE: _____

## ASSIGNMENT

We/I, the undersigned,

Michael G. Bramucci, Andrew C. Eliot, Lori Ann Maggio-Hall, Charles E. Nakamura

(hereafter referred to as the Assignor(s))

for valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell, assign, and transfer to Butamax Advanced Biofuels LLC, a corporation organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Wilmington, Delaware (hereafter referred to as the Assignee), his/her entire right, title, and interest in and to


United States Patent Application No. 14179826, filed on February 13, 2014  
and which is identified as Case Number CL3926USCNT2, entitled  
"A Butanol Dehydrogenase Enzyme from the Bacterium *Achromobacter xylosoxidans*"

in any and all patent applications thereon including non-provisional applications, continuations, continuations-in-part, divisionals, in any and all Letters Patent(s) therefor, reissues, extensions, renewals, and reexaminations of the patent application or Letters Patent therefor, in any and all inventions, whether joint or sole, disclosed therein, any priority rights derived from the aforesaid patent application for Letters Patent by virtue of the International Convention for the Protection of Industrial Property and any other treaty or understanding for intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, any and all applications for Letters Patent for any such inventions in any country whatsoever, any and all patents for any such inventions in any country whatsoever; and the sole right to file such patent applications in its name or ours, file such applications under the aforesaid International Convention or other treaty or understanding, have said patents granted in its name or ours, and enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future. All such rights, title, and interest to be held and enjoyed by the Assignee, its successors, assigns, legal representatives to the same extent as all such rights, title, and interest would have been held and enjoyed by the Assignor(s) had this assignment and sale not been made

We/I, the undersigned, agree, whenever requested, to communicate to Assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers, or instruments necessary or required by Assignee, its successors, assigns, and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid Assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

\_\_\_\_\_(L.S.)  
Michael G. Bramucci

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Lori Ann Maggio-Hall

DATE: 19 Feb 2014

\_\_\_\_\_(L.S.)  
Andrew C. Eliot

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Charles E. Nakamura

DATE: \_\_\_\_\_

## ASSIGNMENT

We/I, the undersigned,

Michael G. Bramucci, Andrew C. Eliot, Lori Ann Maggio-Hall, Charles E. Nakamura

(hereafter referred to as the Assignor(s))

for valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell, assign, and transfer to Butamax Advanced Biofuels LLC, a corporation organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Wilmington, Delaware (hereafter referred to as the Assignee), his/her entire right, title, and interest in and to

United States Patent Application No.14179826, filed on February 13, 2014  
and which is identified as Case Number CL3926USCNT2, entitled  
"A Butanol Dehydrogenase Enzyme from the Bacterium Achromobacter xylosoxidans"

in any and all patent applications thereon including non-provisional applications, continuations, continuations-in-part, divisionals, in any and all Letters Patent(s) therefor, reissues, extensions, renewals, and reexaminations of the patent application or Letters Patent therefor, in any and all inventions, whether joint or sole, disclosed therein, any priority rights derived from the aforesaid patent application for Letters Patent by virtue of the International Convention for the Protection of Industrial Property and any other treaty or understanding for intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, any and all applications for Letters Patent for any such inventions in any country whatsoever, any and all patents for any such inventions in any country whatsoever; and the sole right to file such patent applications in its name or ours, file such applications under the aforesaid International Convention or other treaty or understanding, have said patents granted in its name or ours, and enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future. All such rights, title, and interest to be held and enjoyed by the Assignee, its successors, assigns, legal representatives to the same extent as all such rights, title, and interest would have been held and enjoyed by the Assignor(s) had this assignment and sale not been made

We/I, the undersigned, agree, whenever requested, to communicate to Assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers, or instruments necessary or required by Assignee, its successors, assigns, and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid Assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

\_\_\_\_\_(L.S.)  
Michael G. Bramucci

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Lori Ann Maggio-Hall

DATE: \_\_\_\_\_

\_\_\_\_\_(L.S.)  
Andrew C. Eliot

DATE: \_\_\_\_\_

  
\_\_\_\_\_(L.S.)  
Charles E. Nakamura

DATE: Feb 27, 2014